EMCDDA Home
  • EN
Search

Table HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU, Croatia, Turkey and Norway

Part (iii) Legal framework regarding the dispensing of substitution medications

CountryMETHADONEHIGH DOSAGE BUPRENORPHINEBUPRENORPHINE-NALOXONE COMBINATIONSLOW-RELEASE MORPHINE
specialised treatment centres specialised medical doctors' officesany medical doctor officepharmaciesmobile outreach unitsother providerspecialised treatment centres specialised medical doctors' officesany medical doctor officepharmaciesmobile outreach unitsother providerspecialised treatment centres specialised medical doctors' officesany medical doctor officepharmaciesmobile outreach unitsother providerspecialised treatment centres specialised medical doctors' officesany medical doctor officepharmaciesmobile outreach unitsother provider
Belgium (Flemish community)YYYYYYYY
Belgium (French community)YYYYYYYYY
BulgariaYY
Czech Republic(1)YYYYY
DenmarkYYYYYYYYY(i)
GermanyYYYYY(i)YYYY(i)YYYY(i)
EstoniaYYY
Ireland(2)YYYYY
GreeceYYY
Spain(3)YYYY
FranceYYYYYY
ItalyYYYY(ii)YYYYY(ii)YYYY(ii)YYY
Cyprus
LatviaYYYYY
LithuaniaYYY
LuxembourgYYYYYYYY
HungaryYYYY
Malta
NetherlandsYYYYYYYYYYYYY
AustriaYYYYYY
PolandY
PortugalYYYYYYYYYYYY
RomaniaYYYYYYYY
SloveniaYYYYYYYYYYY
SlovakiaYYY
FinlandYYYY
Sweden
United KingdomYYYYYYYYYYYYYYYY(ii)
CroatiaYYYYYYYYYYYYY
Turkey(4)
NorwayYYYYYYYYY
 

Notes:

'Y' indicates whether a specific provider is involved in dispensing opioid substitution treatment.

Where a specific provider is not allowed to dispense a specific medication, the table entry is left empty. Exception for Malta, Sweden and Croatia for which data were not available .

'Specialized medical doctors' refers to specifically trained or accredited office-based medical doctors or general practitioners practicing outside specialised drug treatment centres.

'Any medical doctor' refers to office-based medical doctors practicing outside specialised drug treatment centres.

(1) In Czech Republic doctors are not dispensing, just prescribing. Pharmacies are selling/dispensing buprenorphine but they are not supervising the consumption.

(2) In Ireland, buprenorphine is provided for substitution in a pilot programme. It does not come under the same legal framework as methadone but does come under the controlled drug legislation.

(3) In Spain, high dosage buprenorphine is not commercially available.

(4) In Turkey Buprenorphine-Naloxone combination treatment is available since 2009.

Other providers:

(i) Hospitals

(ii) Emergency rooms but only under the prescription of a specialised medical doctor

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Structured Questionnaire on 'treatment programmes' (SQ27P1), submitted by NFPs.

Answers from the legal correspondents of the European Legal Database on Drugs (ELDD) to a EMCDDA survey on the legal framework of substitution treatment (2006). See also ELDD topic overview.

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Friday, 26 April 2013